查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
近距离放射治疗设备市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)
市场调查报告书
商品编码
1190135

近距离放射治疗设备市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Brachytherapy Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计近距离放射治疗设备市场在预测期内（2022 年至 2027 年）的复合年增长率为 5.5%。

COVID-19 大流行影响了全球医疗保健系统，也对近距离治疗设备市场产生了重大影响。 根据发表在 Cancer Connect 2020 上的一篇文章，共有 7 名本应接受近距离放射治疗的前列腺癌患者在四家医院接受了治疗。 然而，只有 3 名 (43%) 患者能够接受近距离放射治疗。 根据 2021 年 1 月发表的题为“大流行期间 COVID-19 对近距离放射治疗的影响”的研究。 在 Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience (Advancements in Radiation Oncology) 中，6 名患者选择了 EBRT，随后对不利的中高风险疾病进行了近距离放疗，并发现在大流行期间，4 名患者接受了 EBRT 治疗，有或没有单独的雄激素剥夺疗法 (ADT)，因为择期手术被取消。 儘管卫生系统在大流行期间面临挑战，但大多数癌症患者能够安全地接受治疗，只有轻微的延误或中断。 因此，由于 COVID-19 的限制，它受到了很大的影响。 然而，随着心臟手术的增加，对近距离治疗设备的需求有望推动市场增长。

近距离放射治疗设备通常用于有效治疗妇科、前列腺和乳腺癌等癌症，从而增加了全世界的癌症负担。，预计将对调查市场的增长产生重大影响。 例如，根据国际癌症研究机构（IARC）的数据，2020 年全球癌症发病率估计约为 1930 万，预计到 2030 年将增至 2460 万。 此外，乳腺癌是最常见的癌症之一，2020 年估计有 226 万新病例。 近距离放射治疗是一种利用体内放射性来切除和杀死体内靶点内或附近的癌细胞和肿瘤细胞的治疗方法。 它还与化学疗法、手术和外部放射疗法结合使用。 因此，预计在预测期内，癌症患病率的增加将推动近距离放射治疗市场的增长。

此外，2021 年 10 月，爱丁堡癌症中心宣布将为侵袭性前列腺癌提供高剂量率近距离放射治疗。 该中心是苏格兰首批提供 HDR-BT 治疗前列腺癌的癌症治疗中心之一。 因此，这些努力有望进一步对研究目标市场的增长产生积极影响。

根据国际原子能机构 (IAEA) 放射治疗中心名录 (DIRAC)，到 2020 年，全球放射治疗中心将安装约 3,300 套近距离放射治疗系统，其中约 60% 的癌症患者发生在低危人群中- 和中等收入国家 (LMIC)。 在这些国家，80% 的患者由于获得先进技术产品的机会有限而未接受治疗。 虽然 60-80% 的放射治疗需求在欧洲国家得到满足，但在低收入和中等收入国家 (LMIC) 仅满足 3-4%。 其他因素，如政府加大力度提高微创手术的意识和技术进步，预计将在预测期内推动近距离治疗设备市场。 因此，由于上述因素，近距离放射治疗市场有望在预测期内增长。 然而，缺乏熟练的放射科医生和先进的放射治疗设施、报销问题等是预测期内限制市场增长的主要因素。

主要市场趋势

乳腺癌领域预计在预测期内将录得显着增长

按应用划分，该市场分为妇科癌症、前列腺癌、乳腺癌等，其中与其他癌症类型相比，乳腺癌细分市场有望实现显着增长。 这主要是由于全球范围内乳腺癌患病率的增加。 例如，国际癌症研究机构 (IARC) 2020 年报告提供的估计表明，到 2020 年，全球将诊断出约 230 万新髮乳腺癌病例，超过任何其他形式的癌症。到 2040 年，乳腺癌的发病率预计乳腺癌将达到约300万例，有望提振近距离治疗市场。

乳房内近距离放射治疗也是乳腺癌女性最常见的近距离放射治疗类型。 根据AIARC 2020报告，亚洲地区将是多年来乳腺癌患病率最高的地区之一，其次是欧洲和非洲地区。 因此，乳腺癌的高负担有望增加对乳腺癌治疗的需求，从而促进该细分市场的增长。 此外，旨在提高微创手术意识和技术进步的政府举措不断增加，也促进了近距离放射治疗设备市场的增长。 例如，2021 年 11 月，位于印度恰蒂斯加尔邦的全印度医学科学研究所 (AIIMS) 开始在赖布尔区对包括乳腺癌在内的癌症患者进行近距离放射治疗。 因此，由于上述因素，预计乳腺癌部分在预测期内将占据近距离治疗市场的很大份额。

北美主导市场，预计在预测期内也会如此

由于癌症发病率上升和新技术的早期采用，北美在市场上占据主导地位。 由于患者人数众多和基础设施丰富，美国占据了北美地区的大部分市场。 例如，根据 IARC 2020 报告，北美地区约有 260 万新发癌症病例，预计到 2040 年癌症发病率将增至 350 万。 因此，对近距离放射治疗的需求增加预计将推动该地区的市场增长。

此外，乳腺癌是美国主要的癌症类型之一。 根据美国癌症协会 2022 年 1 月的更新，美国大约每 8 名女性中就有 1 名（约 13%）会在其一生中患上浸润性乳腺癌。 根据同一份报告，到 2022 年，估计美国女性将诊断出 287,850 例浸润性乳腺癌新病例和 51,400 例原位乳腺癌新病例。 据同一消息来源称，预计到 2022 年，男性将诊断出约 2,710 例浸润性乳腺癌新病例。 男性一生患乳腺癌的风险约为 833 分之一。 此外，2021 年 10 月，Susan G. Komen 拨款 150 万美元用于新的研究项目，以调查三个以转移性乳腺癌 (MBC) 为重点的独特领域。 该赠款是 Komen、DUnited Kingdom 癌症研究所和北卡罗来纳大学 Lineberger 综合癌症中心之间创新和首次合作的一部分，即 Susan G. Komen 转移性乳腺癌合作研究计划。 因此，由于上述因素，预计市场在预测期内将出现显着增长。

竞争格局

近距离放射治疗设备市场竞争激烈，由多家大型企业组成。 这些主要参与者中的大多数都享有全球影响力，并在新兴市场面临激烈的竞争。 近距离放射治疗设备市场的主要参与者包括 Argon Medical Devices、Becton、Dickinson and Company、Carl Zeiss Meditec AG、Eckert &Ziegler BEBIG S.A.、Elekta AB、iCAD Inc、Isoray Inc、Theragenics Corporation、Varian Medical Systems Inc。我们提供这些产品

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 癌症发病率增加
    • 政府提高认识的努力变得更加积极
    • 微创手术的技术进步
  • 市场製约因素
    • 缺乏熟练的放射科医生和先进的放射治疗设备
    • 保险报销问题
  • 五力分析分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按技术
    • 高剂量率近距离放射治疗装置
    • 低剂量率近距离放射治疗装置
  • 通过申请
    • 妇科癌症
    • 前列腺癌
    • 乳腺癌
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Argon Medical Devices, Inc.
    • Becton, Dickinson and Company
    • Carl Zeiss Meditec AG
    • Eckert & Ziegler BEBIG S.A.
    • Elekta AB
    • iCAD Inc
    • Isoray Inc
    • Theragenics Corporation
    • Varian Medical Systems Inc
    • CIVCO Medical Solutions
    • Theragenics Corporation
    • Argon Medical

第7章 市场机会今后动向

简介目录
Product Code: 67420

The brachytherapy devices market is projected to register a CAGR of 5.5% during the forecast period (2022-2027).

The COVID-19 pandemic has affected the healthcare systems globally and also has had a significant impact on the Brachytherapy devices market. As per the article published in Cancer Connect 2020, A total of 7 patients with prostate cancer who were scheduled to receive brachytherapy were treated across the 4 hospitals. However, only 3 patients (43%) were able to undergo brachytherapy. As per the study published in January 2021, titled "The Impact of COVID-19 on Brachytherapy During the Pandemic: A Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience", by advances in radiation oncology, six patients elected to undergo EBRT followed by a brachytherapy boost for unfavorable intermediate- and high-risk diseases and since elective surgeries were canceled within the system during the pandemic, 4 patients were treated with EBRT with or without androgen deprivation therapy (ADT) only. Despite the challenges, the health care system faced during the pandemic, most patients with cancer were safely treated with minor treatment delays and interruptions. Thus, due to the COVID-19 imposed restrictions, the was significantly impacted. However, with the increase in cardiac surgeries, the demand for brachytherapy devices is expected to boost the growth of the market.

Brachytherapy devices are commonly used for effectively treating gynecologic, prostate, breast, and other types of cancer and thus increasing the burden of cancer around the world is expected to have a significant impact on the growth of the studied market. For instance, according to the International Agency for Research on Cancer (IARC), the global incidence of cancer in 2020 was estimated to be around 19.3 million, which is expected to increase to 24.6 million by the year 2030. Furthermore, breast cancer is among the most common cancer, with around 2.26 million new cases in 2020. Brachytherapy is related to the implementation of radioactivity within the body, to ablate or kill cancer or tumor cells within, or near the target area in the body. It is also used in combination with chemotherapy, surgery, or external radiation therapy. Thus, the increasing prevalence of cancer is expected to fuel growth in the brachytherapy market over the forecast period.

Moreover, in October 2021, Edinburgh Cancer Center published that it would be offering a high dose rate of brachytherapy for the treatment of aggressive prostate cancer. It is one of the first cancer care centers in Scotland to offer HDR-BT for treating prostate cancer. Hence, initiatives like this are further expected to have a positive impact on the growth of the studied market.

According to the International Atomic Energy Agency's (IAEA) Directory of Radiotherapy Centers (DIRAC), as of 2020, there are around 3,300 brachytherapy systems installed across radiation therapy centers worldwide, of which around 60% of the cancer cases occur in low and low middle-income countries (LMICs). 80% of patients in these countries lack access to treatment as they have limited access to technologically advanced products. In Low and Low Middle-Income Countries (LMICs), only 3-4% of the radiotherapy needs are met as opposed to 60-80% in the European countries. Other factors, such as rising government initiatives to increase awareness and technological advancements in minimally invasive surgical procedures are expected to drive the brachytherapy devices market in the forecast period. Therefore, due to the aforementioned factors, the brachytherapy market is expected to grow over the forecast period. However, the lack of skilled radiologists and advanced radiotherapy facilities, and reimbursement issues are among the major barrier to the growth of this market over the forecast period.

Key Market Trends

Breast Cancer Segment is Expected to Register a Significant Growth Over the Forecast Period

By Application, the market has been segmented into gynecologic cancer, prostate cancer, breast cancer, and others, of which the breast cancer segment is expected to register significant growth as compared to other cancer types. This is majorly attributed to the increasing prevalence of breast cancer across the world. For instance, as per estimates provided by the International Agency for Research on Cancer (IARC) 2020 report, in 2020, about 2.3 million new cases of breast cancer were diagnosed all over the world, more than any other form of cancer and by 2040, the incidence of breast cancer is projected to reach about 3 million cases and thus, with the rising burden of breast cancer, the demand for effective and advanced therapeutics is expected to increase that is expected to boost brachytherapy market over the forecast period.

In addition, intracavitary brachytherapy is one of the most common types of brachytherapy for women with breast cancer and as per the AIARC 2020 report, the Asia region was expected to have one of the highest prevalence of breast cancer over the years followed by Europe and Africa region. Therefore, the high burden of breast cancer is expected to increase the demand for breast cancer treatment, thereby contributing to the market segment growth. Further, rising government initiatives to increase awareness and technological advancements in minimally invasive surgical procedures also contribute to the growth of the brachytherapy devices market. For instance, in November 2021, the All India Institute of Medical Sciences (AIIMS) of Chhattisgarh state India started brachytherapy for cancer patients including breast cancer in the Raipur district. Therefore, owing to the above-mentioned factors, the breast cancer segment is expected to have a significant market share in the brachytherapy market over the forecast period.

North America Dominates the Market and Expected to do the Same Over the Forecast Period

North America dominates the market owing to the increasing incidences of cancer and early adoption of new technologies. United States holds the majority of the market in the North American region due to its high patient pool and well-developed infrastructure. For instance, according to the IARC 2020 report, approximately 2.6 million new cases of cancer were recorded in the North American region and by 2040, the incidence of cancer is expected to increase to 3.5 million cancer cases. Hence, the demand for brachytherapy is expected to increase in the region which is anticipated to drive market growth.

Moreover, in United States, breast cancer is one of the leading cancer types. According to the January 2022 update by the American Cancer Society, about 1 in 8 United States women (about 13%) will develop invasive breast cancer throughout their lifetime. The same source reports that in 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in United States, along with 51,400 new cases of non-invasive (in situ) breast cancer. As per the same source, about 2,710 new cases of invasive breast cancer are expected to be diagnosed in men in 2022. A man's lifetime risk of breast cancer is about 1 in 833. Furthermore, in October 2021, Susan G. Komen awarded USD 1.5 million for three new research projects that examine three unique areas focused on metastatic breast cancer (MBC). The grants are part of the Susan G. Komen Metastatic Breast Cancer Collaborative Research Initiative, an innovative, first-of-its-kind collaboration between Komen, Duke Cancer Institute, and the University of North Carolina Lineberger Comprehensive Cancer Center. Thus, due to the above-mentioned factors, the market is expected to witness significant growth during the forecast period.

Competitive Landscape

The Brachytherapy Devices market is fairly competitive and consists of several major players. Most of these major players enjoy a global presence, and they are facing intense competition in emerging economies. The major players in the brachytherapy devices market includes Argon Medical Devices, Becton, Dickinson and Company, Carl Zeiss Meditec AG, Eckert & Ziegler BEBIG S.A., Elekta AB, iCAD Inc., Isoray Inc., Theragenics Corporation, and Varian Medical Systems Inc., which provides these products across the globe.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Cancer
    • 4.2.2 Rising Government Initiatives to Increase Awareness
    • 4.2.3 Technological Advancements in Minimally Invasive Surgical Procedures
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Radiologists and Advanced Radiotherapy Facilities
    • 4.3.2 Reimbursement Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Technique
    • 5.1.1 High Dose Rate Brachytherapy Devices
    • 5.1.2 Low Dose Rate Brachytherapy Devices
  • 5.2 By Application
    • 5.2.1 Gynecologic Cancer
    • 5.2.2 Prostrate Cancer
    • 5.2.3 Breast Cancer
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Argon Medical Devices, Inc.
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Carl Zeiss Meditec AG
    • 6.1.4 Eckert & Ziegler BEBIG S.A.
    • 6.1.5 Elekta AB
    • 6.1.6 iCAD Inc
    • 6.1.7 Isoray Inc
    • 6.1.8 Theragenics Corporation
    • 6.1.9 Varian Medical Systems Inc
    • 6.1.10 CIVCO Medical Solutions
    • 6.1.11 Theragenics Corporation
    • 6.1.12 Argon Medical

7 MARKET OPPORTUNITIES AND FUTURE TRENDS